Previous studies have shown that loss-of-function mutations in STK11, KEAP1, and SMARCA4 drive primary resistance to ICI in lung cancer.15,16 Here, we demonstrate that these alterations can also mediate AR to ICI. This evidence concerns the gene STK11 and lung carcinoma.